Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASH 2022 ALL Highlights

12 January 2023 | Virtual Meeting

Post-ASH 2022 ALL Highlights

12 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in ALL from ASH 2022

The Post-ASH 2022 ALL Highlights virtual workshop was held on 12 January 2023, featuring a series of short presentations on selected abstracts from the 64th ASH Annual Meeting presented by experts with interactive panel discussions after each session.

MRD and multi-agent chemotherapy Targeted treatments – blinatumomab Targeted treatments – inotuzumab ozogamicin Current clinical updates for CAR-T Clinical strategies for Ph+/like ALL

Session 1: MRD-led treatment outcomes and considerations for multi-agent chemotherapy

Nicolas Boissel
Results from the GRAALL-2014 trial
Nicolas Boissel Saint-Louis Hospital, Paris, France
Luke Maese
Results from the AALL1931 study
Luke Maese University of Utah Health, Salt Lake City, UT, United States
Panel discussion

Session 2: Targeted treatments in B-cell ALL – blinatumomab

Elias Jabbour
Safety run-in results for the Golden Gate study
Elias Jabbour University of Texas MD Anderson Cancer Center, Houston, TX, United States
Nicolas Boissel
A two-cohort comparison within the GRAALL-2014/B study
Nicolas Boissel Saint-Louis Hospital, Paris, France
Mark Litzow
ECOG-ACTIN-E1910 NCTN clinical trial
Mark Litzow Mayo Clinic, Rochester, MN, United States
Cyril Salek
Primary endpoint analysis of the Blina-CELL trial
Cyril Salek Institute of Haematology and Blood Transfusion, Prague, Czech Republic
Panel discussion

Session 3: Targeted treatments in B-cell ALL – inotuzumab ozogamicin

Jayastu Senapati
Inotuzumab ozogamicin for the treatment of MRD-positive B-cell ALL
Jayastu Senapati MD Anderson Cancer Center, Houston, TX, United States
Nicholas Short
Addition of INO with hyper-CVAD plus blinatumomab for B-ALL
Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion

Session 4: Current clinical updates for CAR-T in B-ALL

Bijal Shah
Updated outcomes from the SCHOLAR-3 trial
Bijal Shah H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Claire Roddie
Safety, efficiency and long-term follow-up of AUTO1
Claire Roddie University College London, London, United Kingdom
Regina Myers
CD22-targeted CAR-modified T-cells in children & young adults
Regina Myers Children's Hospital of Philadelphia, Philadelphia, PA, United States
Panel discussion

Session 5: Clinical strategy updates for patients with Ph+/like ALL

Sarah Tasian
Results of the AALL1521 study (NCB18424-269)
Sarah Tasian Children's Hospital of Philadelphia, Philadelphia, PA, United States
Nicholas Short
Ponatinib and blinatumomab for newly diagnosed patients with Ph+ ALL
Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Ibrahim Aldoss
Novel salvage therapies for adults with ALL with Ph-like fusions
Ibrahim Aldoss City of Hope, Duarte, CA, United States
Panel discussion

The continued success of the iwAL meeting is in no small part due to the ongoing funding of supporters, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future iwAL meetings and activities, please contact us here.

For the latest updates in ALL, visit The ALL Channel

The content of VJHemOnc is intended for healthcare professionals